TAPO in first‐line osimertinib therapy and continuation of osimertinib

Abstract Background Osimertinib is associated with a relatively high frequency of drug‐induced interstitial lung disease (D‐ILD), and transient asymptomatic pulmonary opacities (TAPO) have been reported to occur during osimertinib administration. The frequency of TAPO during first‐line treatment and...

詳細記述

書誌詳細

出版年:	Thoracic Cancer
主要な著者:	Chihiro Mimura, Kazumi Kaneshiro, Shodai Fujimoto, Ryota Dokuni, Natsuhiko Iwamoto, Kanoko Matsumura, Yukihisa Hatakeyama, Yuko Kono, Motoko Tachihara
フォーマット:	論文
言語:	英語
出版事項:	Wiley 2023-02-01
主題:	interstitial lung disease lung cancer NSCLC transient asymptomatic pulmonary opacity (TAPO)
オンライン･アクセス:	https://doi.org/10.1111/1759-7714.14782